Author

I Bradbury

Institutions: Aarhus University, Peterborough City Hospital, Skåne University Hospital, Bayer (Germany), Cardiff University

Observed institutions: Université Libre de Bruxelles, Mayo Clinic, Memorial Sloan Kettering Cancer Center, GlaxoSmithKline (United Kingdom), Universität Ulm, Universidad Peruana Cayetano Heredia, Chinese Academy of Medical Sciences & Peking Union Medical College, Aarhus University, Peterborough City Hospital, University Hospital of Bern, Institut Jules Bordet, Christian-Albrechts-Universität zu Kiel, Yale University, Breast International Group, University of Belgrade, Massachusetts General Hospital, Roche (Belgium), University Hospital Schleswig-Holstein, Roche (United Kingdom), Royal Marsden Hospital, German Breast Group, Skåne University Hospital, Frontier Science & Technology Research Foundation, Inc., Sana Klinikum Offenbach, Mayo Clinic in Florida, Helios Hospital Berlin-Buch, Vall d'Hebron Institute of Oncology, Bayer (Germany), Cardiff University, Ludwig-Maximilians-Universität München

OpenAlex ID: A5046030472

OT1-02-04: Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4–11/BO25126/TOC4939g).

2011 · Minckwitz G von, J Baselga, et al. · Cancer Research · 11

Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial

2016 · HA Azim, A Sonnenblick, et al. · Cancer Research · 6

Abstract P1-08-42: High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial

2013 · M Scaltriti, P Nuciforo, et al. · Cancer Research · 2

Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

2017 · E de Azambuja, I Bradbury, et al. · Cancer Research · 1

Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial

2013 · DL Rimm, E Holmes, et al. · Cancer Research · 1

Radiotherapy in small cell cancer of the lung

1984 · R L Souhami, J S Tobias, et al. · BMJ · 1

Abstract P2-03-02: Markers of PI3K/Akt, ER & AR pathways and Ki67 expression in relation to tamoxifen outcome in ER+ breast cancer

2019 · C Campbell, J Mathew, et al. · Cancer Research

Decision science in cancer research: Evaluation of FDG-PET in the surgical management of NSCLC

2005 · George Laking, I Bradbury, et al. · ePrints Soton (University of Southampton)

Works count: 8

Citation count: 22

H-index: 2

I10-index: 1